Rock Springs Capital's portfolio at a glance (Q2 2026 13F)
Rock Springs Capital's latest Form 13F covers Q2 2026 and was filed with the SEC on 2026-08-14. It lists 104 US stock positions worth about $2.0 billion.
The largest holdings are Revolution Medicines Inc (RVMD) at 10.1%, Travere Therapeutics Inc (TVTX) at 6.0%, Eli Lilly & Co (LLY) at 5.8%, Madrigal Pharmaceuticals Inc (MDGL) at 4.6%, Mirum Pharmaceuticals Inc (MIRM) at 4.6% of the portfolio.
Compared with the previous quarter, Rock Springs Capital opened 17 new positions (biggest: Ascendis Pharma A/S, Avalyn Pharmaceuticals Inc (AVLN), Hemab Therapeutics Hldgs Inc (COAG)), sold out of 13 (biggest: Ascendis Pharma A/S, Arcellx Inc, Centessa Pharmaceuticals Plc), added to 39, trimmed 30.
Rock Springs Capital's top 10 holdings, Q2 2026
| # | Holding | Share of portfolio |
|---|---|---|
| 1 | Revolution Medicines Inc (RVMD) | 10.1% |
| 2 | Travere Therapeutics Inc (TVTX) | 6.0% |
| 3 | Eli Lilly & Co (LLY) | 5.8% |
| 4 | Madrigal Pharmaceuticals Inc (MDGL) | 4.6% |
| 5 | Mirum Pharmaceuticals Inc (MIRM) | 4.6% |
| 6 | Rhythm Pharmaceuticals Inc (RYTM) | 3.8% |
| 7 | Kymera Therapeutics Inc (KYMR) | 2.5% |
| 8 | Argenx Se - Adr (ARGX) | 2.4% |
| 9 | Ascendis Pharma A/S (K08588103) | 2.2% |
| 10 | Xenon Pharmaceuticals Inc (XENE) | 2.0% |
94 more positions, with shares, values and each one's history, are in RetailVest Pro.
What Rock Springs Capital bought and sold in Q2 2026
- Opened · 17 positions, the biggest:
- Ascendis Pharma A/S; Avalyn Pharmaceuticals Inc (AVLN); Hemab Therapeutics Hldgs Inc (COAG)
- Added to · 39 positions, the biggest:
- Travere Therapeutics Inc (TVTX) (+47% shares); Madrigal Pharmaceuticals Inc (MDGL) (+2% shares); Rhythm Pharmaceuticals Inc (RYTM)
- Trimmed · 30 positions, the biggest:
- Revolution Medicines Inc (RVMD) (-9% shares); Mirum Pharmaceuticals Inc (MIRM) (-2% shares); Kymera Therapeutics Inc (KYMR) (-9% shares)
- Closed · 13 positions, the biggest:
- Ascendis Pharma A/S; Arcellx Inc; Centessa Pharmaceuticals Plc
Source: Form 13F filed with the SEC on 2026-08-14 (EDGAR). Start a 7-day free trial to see every position, every change on the quarter and the filing history.
Questions about Rock Springs Capital's 13F
- What stocks does Rock Springs Capital own?
- As of the Q2 2026 13F filing, Rock Springs Capital's largest US stock holdings are Revolution Medicines Inc (RVMD), 10.1%; Travere Therapeutics Inc (TVTX), 6.0%; Eli Lilly & Co (LLY), 5.8%; Madrigal Pharmaceuticals Inc (MDGL), 4.6%; Mirum Pharmaceuticals Inc (MIRM), 4.6%.
- What is Rock Springs Capital buying and selling?
- Compared with the previous quarter, Rock Springs Capital opened 17 new positions (biggest: Ascendis Pharma A/S, Avalyn Pharmaceuticals Inc (AVLN), Hemab Therapeutics Hldgs Inc (COAG)), sold out of 13 (biggest: Ascendis Pharma A/S, Arcellx Inc, Centessa Pharmaceuticals Plc), added to 39, trimmed 30.
- When will Rock Springs Capital file the next 13F?
- 13F filings are due 45 days after each quarter ends, so the next one is due by about 2026-11-14.
- How current is 13F data?
- A 13F shows long US stock and option positions at the end of a quarter and can be up to 45 days old when filed. It doesn't show short positions, cash, bonds or non-US holdings.
Email me when Rock Springs Capital files a new 13F
One email when the next quarterly filing shows up on SEC EDGAR, with what was bought and sold.
We'll only email you about this. Unsubscribe anytime.
